PL3054927T3 - Preparaty (s)-3-(4-((4-(morfolinometylo)benzyl)oksy)-1- oksoizoindolin-2-ylo)piperydyno-2,6-dionu - Google Patents

Preparaty (s)-3-(4-((4-(morfolinometylo)benzyl)oksy)-1- oksoizoindolin-2-ylo)piperydyno-2,6-dionu

Info

Publication number: PL3054927T3
Authority: PL; Poland
Prior art keywords: oxoisoindolin; morpholinomethyl; benzyloxy; dione; piperidine
Prior art date: 2013-10-08

Application number

PL14786429T

Other languages

English (en)

Inventor

Darshan PARIKH

Anil Menon

Original Assignee

Celgene Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-10-08

Filing date

2014-10-07

Publication date

2019-08-30

2014-10-07 Application filed by Celgene Corporation filed Critical Celgene Corporation

2019-08-30 Publication of PL3054927T3 publication Critical patent/PL3054927T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Oil, Petroleum & Natural Gas (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Neurology (AREA)
Inorganic Chemistry (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Reproductive Health (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Neurosurgery (AREA)

PL14786429T 2013-10-08 2014-10-07 Preparaty (s)-3-(4-((4-(morfolinometylo)benzyl)oksy)-1- oksoizoindolin-2-ylo)piperydyno-2,6-dionu PL3054927T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361888419P	2013-10-08	2013-10-08
PCT/US2014/059424 WO2015054199A1 (en)	2013-10-08	2014-10-07	Formulations of (s)-3-(4-((4-(morpholinomethyl)benzyloxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
EP14786429.2A EP3054927B1 (en)	2013-10-08	2014-10-07	Formulations of (s)-3-(4-((4-(morpholinomethyl)benzyloxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione

Publications (1)

Publication Number	Publication Date
PL3054927T3 true PL3054927T3 (pl)	2019-08-30

Family

ID=51743584

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL14786429T PL3054927T3 (pl)	2013-10-08	2014-10-07	Preparaty (s)-3-(4-((4-(morfolinometylo)benzyl)oksy)-1- oksoizoindolin-2-ylo)piperydyno-2,6-dionu

Country Status (34)

Country	Link
US (2)	US10080801B2 (pl)
EP (1)	EP3054927B1 (pl)
JP (1)	JP6562907B2 (pl)
KR (1)	KR102272274B1 (pl)
CN (1)	CN105899196B (pl)
AR (1)	AR100663A1 (pl)
AU (1)	AU2014332171C1 (pl)
BR (1)	BR112016007729B1 (pl)
CA (1)	CA2921436C (pl)
CL (1)	CL2016000816A1 (pl)
CR (1)	CR20160131A (pl)
CY (1)	CY1121689T1 (pl)
DK (1)	DK3054927T3 (pl)
EA (1)	EA032421B1 (pl)
ES (1)	ES2723891T3 (pl)
HR (1)	HRP20190733T1 (pl)
HU (1)	HUE044186T2 (pl)
IL (1)	IL244494B (pl)
LT (1)	LT3054927T (pl)
MX (1)	MX2016004342A (pl)
NI (1)	NI201600048A (pl)
NZ (1)	NZ716856A (pl)
PE (1)	PE20160550A1 (pl)
PH (1)	PH12016500301A1 (pl)
PL (1)	PL3054927T3 (pl)
PT (1)	PT3054927T (pl)
RS (1)	RS58688B1 (pl)
SA (1)	SA516370860B1 (pl)
SG (1)	SG11201600996UA (pl)
SI (1)	SI3054927T1 (pl)
TR (1)	TR201905874T4 (pl)
TW (1)	TW201605493A (pl)
UA (1)	UA117141C2 (pl)
WO (1)	WO2015054199A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2536706B1 (en)	2010-02-11	2017-06-14	Celgene Corporation	Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
US20150038511A1 (en)	2012-08-09	2015-02-05	Celgene Corporation	Treatment of immune-related and inflammatory diseases
KR102266509B1 (ko)	2012-08-09	2021-06-16	셀진 코포레이션	면역-관련 및 염증성 질환의 치료
US9695145B2 (en)	2013-01-22	2017-07-04	Celgene Corporation	Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
EP3145513B1 (en)	2014-05-19	2023-11-15	Celgene Corporation	3-(4-((4-(morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
BR112021006318A2 (pt) *	2018-10-01	2021-07-06	Celgene Corp	terapia de combinação para o tratamento de câncer
CN113597301A (zh) *	2019-01-09	2021-11-02	细胞基因公司	包含(s)-4-(4-(4-(((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-4-基)氧基)甲基)苄基)哌嗪-1-基)-3-氟苄腈的药物组合物以及使用它的方法
US20220401483A1 (en)	2019-11-07	2022-12-22	Juno Therapeutics, Inc.	Combination of a t cell therapy and (s)-3-[4-(4-morpholin-4-ylmethyl-benzyloxy)-l-oxo-l,3-dihydro-isoindol-2-yl]-piperidine-2,6-dione
JP2023531512A (ja) *	2020-06-25	2023-07-24	セルジーンコーポレーション	併用療法を用いて癌を治療するための方法
US20220168403A1 (en) *	2020-07-17	2022-06-02	Geron Corporation	Subcutaneous telomerase inhibitor compositions and methods for using same
WO2024064646A1 (en)	2022-09-20	2024-03-28	Celgene Corporation	Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995003009A1 (en)	1993-07-22	1995-02-02	Oculex Pharmaceuticals, Inc.	Method of treatment of macular degeneration
US5770589A (en)	1993-07-27	1998-06-23	The University Of Sydney	Treatment of macular degeneration
IT1274549B (it)	1995-05-23	1997-07-17	Indena Spa	Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno
US5800819A (en)	1996-01-25	1998-09-01	National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology	Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
US6281230B1 (en)	1996-07-24	2001-08-28	Celgene Corporation	Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en)	1996-07-24	1999-06-29	Celgene Corp	Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6015803A (en)	1998-05-04	2000-01-18	Wirostko; Emil	Antibiotic treatment of age-related macular degeneration
US6225348B1 (en)	1998-08-20	2001-05-01	Alfred W. Paulsen	Method of treating macular degeneration with a prostaglandin derivative
US6001368A (en)	1998-09-03	1999-12-14	Protein Technologies International, Inc.	Method for inhibiting or reducing the risk of macular degeneration
CN1511420A (zh)	2001-11-09	2004-07-07	松下电器产业株式会社	运动图像编码方法和装置
US7498171B2 (en)	2002-04-12	2009-03-03	Anthrogenesis Corporation	Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7323479B2 (en)	2002-05-17	2008-01-29	Celgene Corporation	Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7189740B2 (en)	2002-10-15	2007-03-13	Celgene Corporation	Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20050203142A1 (en)	2002-10-24	2005-09-15	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en)	2002-10-31	2004-05-13	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en)	2002-11-06	2009-07-21	Celgene Corporation	Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
UA83504C2 (en)	2003-09-04	2008-07-25	Селджин Корпорейшн	Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20050100529A1 (en)	2003-11-06	2005-05-12	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
US20050143344A1 (en)	2003-12-30	2005-06-30	Zeldis Jerome B.	Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
ZA200607799B (en)	2004-03-22	2008-06-25	Celgene Corp	Methods of using and compositions comprising immuno-modulatory compounds for the treatment and management of skin diseases or disorders
WO2005105088A2 (en)	2004-04-23	2005-11-10	Celgene Corporation	Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
BRPI0517481A (pt)	2004-11-12	2008-10-14	Celgene Corp	método para tratar, controlar ou evitar uma doença ou distúrbio parasìtico protozoário, e, composição farmacêutica
WO2006058008A1 (en)	2004-11-23	2006-06-01	Celgene Corporation	Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
AU2006265019B2 (en)	2005-06-30	2011-10-13	Celgene Corporation	Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds
WO2007027527A2 (en)	2005-08-31	2007-03-08	Celgene Corporation	Isoindole-imide compounds and compositions comprising and methods of using the same
CA2660806C (en)	2006-08-30	2015-06-16	Celgene Corporation	5-substituted isoindoline compounds
US8877780B2 (en)	2006-08-30	2014-11-04	Celgene Corporation	5-substituted isoindoline compounds
EP2076260B1 (en)	2006-09-15	2011-03-23	Celgene Corporation	N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same
DK2420498T3 (en)	2006-09-26	2017-08-14	Celgene Corp	5-substituted quinazolinone derivatives as anticancer agents
JP2010522170A (ja)	2007-03-20	2010-07-01	セルジーンコーポレイション	４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法
PT3351240T (pt)	2009-05-19	2019-06-21	Celgene Corp	Formulações de 4-amino-2-(2,6-dioxopiperidin-3-il) isoindolino-1,3-diona
EP2536706B1 (en) *	2010-02-11	2017-06-14	Celgene Corporation	Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same

2014
- 2014-07-10 UA UAA201605023A patent/UA117141C2/uk unknown
- 2014-10-07 WO PCT/US2014/059424 patent/WO2015054199A1/en active Application Filing
- 2014-10-07 ES ES14786429T patent/ES2723891T3/es active Active
- 2014-10-07 MX MX2016004342A patent/MX2016004342A/es unknown
- 2014-10-07 AU AU2014332171A patent/AU2014332171C1/en active Active
- 2014-10-07 JP JP2016521344A patent/JP6562907B2/ja active Active
- 2014-10-07 TW TW103134936A patent/TW201605493A/zh unknown
- 2014-10-07 RS RS20190490A patent/RS58688B1/sr unknown
- 2014-10-07 LT LTEP14786429.2T patent/LT3054927T/lt unknown
- 2014-10-07 HU HUE14786429 patent/HUE044186T2/hu unknown
- 2014-10-07 DK DK14786429.2T patent/DK3054927T3/da active
- 2014-10-07 KR KR1020167009333A patent/KR102272274B1/ko active IP Right Grant
- 2014-10-07 PE PE2016000431A patent/PE20160550A1/es unknown
- 2014-10-07 SI SI201431178T patent/SI3054927T1/sl unknown
- 2014-10-07 CA CA2921436A patent/CA2921436C/en active Active
- 2014-10-07 EP EP14786429.2A patent/EP3054927B1/en active Active
- 2014-10-07 EA EA201690741A patent/EA032421B1/ru not_active IP Right Cessation
- 2014-10-07 BR BR112016007729-6A patent/BR112016007729B1/pt active IP Right Grant
- 2014-10-07 AR ARP140103744A patent/AR100663A1/es unknown
- 2014-10-07 SG SG11201600996UA patent/SG11201600996UA/en unknown
- 2014-10-07 PL PL14786429T patent/PL3054927T3/pl unknown
- 2014-10-07 NZ NZ716856A patent/NZ716856A/en unknown
- 2014-10-07 TR TR2019/05874T patent/TR201905874T4/tr unknown
- 2014-10-07 CN CN201480055238.2A patent/CN105899196B/zh active Active
- 2014-10-07 US US14/508,719 patent/US10080801B2/en not_active Ceased
- 2014-10-07 PT PT14786429T patent/PT3054927T/pt unknown
2016
- 2016-02-12 PH PH12016500301A patent/PH12016500301A1/en unknown
- 2016-03-08 IL IL244494A patent/IL244494B/en active IP Right Grant
- 2016-03-15 CR CR20160131A patent/CR20160131A/es unknown
- 2016-04-03 SA SA516370860A patent/SA516370860B1/ar unknown
- 2016-04-06 NI NI201600048A patent/NI201600048A/es unknown
- 2016-04-08 CL CL2016000816A patent/CL2016000816A1/es unknown
2019
- 2019-04-17 HR HRP20190733TT patent/HRP20190733T1/hr unknown
- 2019-05-03 CY CY20191100467T patent/CY1121689T1/el unknown
2020
- 2020-09-23 US US17/030,272 patent/USRE49647E1/en active Active

Also Published As

Publication number	Publication date
JP6562907B2 (ja)	2019-08-21
EA201690741A1 (ru)	2016-07-29
BR112016007729B1 (pt)	2023-05-16
UA117141C2 (uk)	2018-06-25
TR201905874T4 (tr)	2019-05-21
CL2016000816A1 (es)	2017-03-10
AR100663A1 (es)	2016-10-26
SG11201600996UA (en)	2016-03-30
JP2016532657A (ja)	2016-10-20
NZ716856A (en)	2021-12-24
WO2015054199A1 (en)	2015-04-16
CN105899196A (zh)	2016-08-24
CA2921436A1 (en)	2015-04-16
PH12016500301A1 (en)	2016-05-02
MX2016004342A (es)	2016-07-05
KR20160067118A (ko)	2016-06-13
EP3054927B1 (en)	2019-02-20
AU2014332171C1 (en)	2020-03-26
CN105899196B (zh)	2020-02-14
TW201605493A (zh)	2016-02-16
SA516370860B1 (ar)	2018-08-14
EP3054927A1 (en)	2016-08-17
WO2015054199A8 (en)	2016-05-06
KR102272274B1 (ko)	2021-07-05
CR20160131A (es)	2016-07-27
PE20160550A1 (es)	2016-05-21
IL244494B (en)	2020-05-31
USRE49647E1 (en)	2023-09-12
AU2014332171B2 (en)	2019-09-12
HUE044186T2 (hu)	2019-10-28
BR112016007729A2 (pl)	2017-08-01
CA2921436C (en)	2022-01-04
RS58688B1 (sr)	2019-06-28
AU2014332171A1 (en)	2016-04-14
SI3054927T1 (sl)	2019-06-28
US10080801B2 (en)	2018-09-25
ES2723891T3 (es)	2019-09-03
PT3054927T (pt)	2019-05-29
NI201600048A (es)	2016-05-20
LT3054927T (lt)	2019-07-10
US20150099745A1 (en)	2015-04-09
CY1121689T1 (el)	2020-07-31
IL244494A0 (en)	2016-04-21
DK3054927T3 (da)	2019-05-13
HRP20190733T1 (hr)	2019-06-14
EA032421B1 (ru)	2019-05-31

Publication	Publication Date	Title
SG11201600996UA (en)	2016-03-30	Formulations of (s)-3-(4-((4-(morpholinomethyl)benzyloxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
IL288506A (en)	2022-01-01	Methods for treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoisoindolin-2-yl)piperidine-2,6-dione
HK1211576A1 (en)	2016-05-27	Salts and solid forms of (s) -3-(4-((4-morpholinomethyl)benzyl)oxy)- 1-oxoisoindolin-2-yl) piperidine-2,6-dione and compositions comprising and methods of using the same (s)-3-(4-((4-()))-1--2-)-26-
HK1211577A1 (en)	2016-05-27	Processes for the preparation of (s)-3-4- ((4-(morpholinomethyl) benzyl)oxy)-1-oxoisoindolin-2-yl) piperidine-2,6-dione and pharmaceutically acceptable forms thereof (s)-3-(4-((4-()))-1--2-)- 26-
SG11201508836XA (en)	2015-11-27	Synthesis of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2,6-dione
HK1252415A1 (zh)	2019-05-24	包含3-(5-氨基-2-甲基-4-氧代基-4h-喹唑啉-3-基)-呱啶-2，6-二酮的藥物組合物
GB201807634D0 (en)	2018-06-27	Novel levothyroxine formulations for oral use
TH1501006617A (th)	2017-06-15	การสังเคราะห์ 3-(5อะมิโน-2-เมธิล-4-ออกโซควินาโซลิน-3(4h)-อิล)ไพเพอริดีน-2,6-ไดโอน
TH1501000645A (th)	2016-09-06	เกลือและรูปของแข็งของ(s)-3-(4-((4-มอร์ฟอลิโนเมธิล)เบนซิล)ออกซิ)-1-ออกโซไอโซอินโดลิน-2-อิล)ไพเพอริดีน-2,6-ไดโอน และองค์ประกอบซึ่งประกอบรวมด้วย และวิธีของการใช้สารเดียวกัน